Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Issue 3 (17th May 2019)

• Record Type: Journal Article
• Authors: Dohan, Anthony; Gallix, Benoit; Guiu, Boris; Le Malicot, Karine; Reinhold, Caroline; Soyer, Philippe; Bennouna, Jaafar; Ghiringhelli, Francois; Barbier, Emilie; Boige, Valérie; Taieb, Julien; Bouché, Olivier; François, Eric; Phelip, Jean-Marc; Borel, Christian; Faroux, Roger; Seitz, Jean-Francois; Jacquot, Stéphane; Ben Abdelghani, Meher; Khemissa-Akouz, Faiza; Genet, Dominique; Jouve, Jean Louis; Rinaldi, Yves; Desseigne, Françoise; Texereau, Patrick; Suc, Etienne; Lepage, Come; Aparicio, Thomas; Hoeffel, Christine
• Other Names: author non-byline.; Volet Julien author non-byline.; Kirscher Sylvie author non-byline.; Delique Laurence author non-byline.; Rougier Philippe author non-byline.; Lepere Céline author non-byline.; Dubreuil Olivier author non-byline.; Zaanan Aziz author non-byline.; Medinger Guillaume author non-byline.; Adenis Antoine author non-byline.; Hajbi Farid El author non-byline.; Sailliant Gilles Gatineau author non-byline.; Locher Christophe author non-byline.; Etienne Pierre-Luc author non-byline.; Denes Sandrine Lavau author non-byline.; Lecomte Thierry author non-byline.; Hautefeuille Vincent author non-byline.; Coriat Romain author non-byline.; Tougeron David author non-byline.; Baconnier Mathieu author non-byline.; Michel Pierre author non-byline.; Blondin Valérie author non-byline.; Capitain Olivier Joseph author non-byline.; Villing Anne-Laure author non-byline.; Boulat Olivier author non-byline.; Queuniet Anne-Marie author non-byline.; Le Tallec Véronique Jestin author non-byline.; Herve Robert author non-byline.; Sebbagh Virginie author non-byline.; Baumgaertner Isabelle author non-byline.; Boschetti Gilles author non-byline.; Aouakli Amar author non-byline.; Mitry Emmanuel author non-byline.; Carola Elisabeth author non-byline.; Bedjaoui Ahmed author non-byline.; Castanie Hélène author non-byline.; Douillard Jean-yves author non-byline.; Senellart Hélène author non-byline.; Hiret Sandrine author non-byline.; Lorgis Véronique author non-byline.; Vincent Aude author non-byline.; Ducreux Michel author non-byline.; Burtin Pascal author non-byline.; Malka David author non-byline.; Zrihen Elie author non-byline.; Hollebecque Antoine author non-byline.; Landi Bruno author non-byline.; Trouilloud Isabelle author non-byline.; Follana Philippe author non-byline.; Coulaud Xavier author non-byline.; Borel Christian author non-byline.; Belletier Christine author non-byline.; Dewaele François author non-byline.; Chatellier Thierry author non-byline.; Dahan Laétitia author non-byline.; Duluc Muriel author non-byline.; Monnereau Emmanuelle Norguet author non-byline.; Becht Catherine author non-byline.; Lafforgue Béatrice author non-byline.; Janssen Eric author non-byline.; Bedenne Laurent author non-byline.; Lepage Côme author non-byline.; Haineaux Paul Arthur author non-byline.; Audemar Franck author non-byline.; La Fouchardiere Christelle De author non-byline.; Dauba Jérôme author non-byline.; Becouarn Yves author non-byline.; Bechade Dominique author non-byline.; Cany Laurent author non-byline.; Levache Charles-Briac author non-byline.; Barriere Nicolas author non-byline.; Bachet Jean-Baptiste author non-byline.; Mansourbakht Touraj author non-byline.; Rob Lynn author non-byline.; Conroy Thierry author non-byline.; Kaminsky Marie-christine author non-byline.; Cumin Isabelle author non-byline.; Egreteau Joëlle author non-byline.; Lamy Régine author non-byline.; Gornet Jean-Marc author non-byline.; Cojocarasu Oana author non-byline.; Gasmi Mohamed author non-byline.; Luet Dominique author non-byline.; Caroli-bosc François-xavier author non-byline.; Roquin Guillaume author non-byline.; Couffon Caroline author non-byline.; Linot Benjamin author non-byline.; Guerin-Meyer Véronique author non-byline.; Nguyen Suzanne author non-byline.; Gerardin Nathalie author non-byline.; Carreiro Miguel author non-byline.; Sarda Corinne author non-byline.; Laurens Nathalie Hess author non-byline.; Molin Yann author non-byline.; Lombard-Bohas Catherine author non-byline.; Walter Thomas author non-byline.; Forestier Julien author non-byline.; Salloum Hatem author non-byline.; Boussaha Farah Zerouala author non-byline.; Corina cornila Jérôme Meunier author non-byline.; Stefani Laetitia author non-byline.; Maillard Christian author non-byline.; Porneuf Marc author non-byline.; Quentin Vincent author non-byline.; Giraud Claire author non-byline.; Vantelon Jean-marie author non-byline.; Lagnes Anne Cadier author non-byline.; Ramdani Mohammed author non-byline.; Bricquir Yann Le author non-byline.; Kikolski Florence author non-byline.; Goujon Gaël author non-byline.; Terrebonne Eric author non-byline.; Vergniol Julien author non-byline.; Pesque-penaud Sophie author non-byline.; Gouttebel Marie-claude author non-byline.; Gasnault Laurent author non-byline.; Alessio Annunziato author non-byline.; Graber Ivan author non-byline.; Danquechin Etienne Dorval author non-byline.; Gargot Dany author non-byline.; Bourgeois Vincent author non-byline.; Queuniet Anne-Marie author non-byline.; Robiche Dominique Sevin author non-byline.; Lagraniere Stéfanie Oddou author non-byline.; Ezenfis Joël author non-byline.; Verge Denis Pere author non-byline.; Jean-Christophe Souquet author non-byline.; Wander Lionel author non-byline.; Mahamat Abakar Abakar author non-byline.; Cretin Jacques author non-byline.; Gossart Anne-claire Dupont author non-byline.; Martin Philippe author non-byline.; Boilleau-jolimoy Geneviève author non-byline.; Bidault Anne Thirot author non-byline.; Azzedine Ahmed author non-byline.; Ladhib Zied author non-byline.;
• Is Part Of: Gut. Volume 69:Issue 3(2020)
• Page Start: 531
• Page End: 539
• Publication Date: 2019-05-17
• Subjects: chemotherapy -- clinical decision making -- colorectal cancer -- colorectal metastases -- computerised image analysis; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2018-316407
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Purpose: The objective of this study was to build and validate a radiomic signature to predict early a poor outcome using baseline and 2-month evaluation CT and to compare it to the RECIST1·1 and morphological criteria defined by changes in homogeneity and borders. Methods: This study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal cancer (mCRC) treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab had been analysed. In 230 patients, computed texture analysis was performed on the dominant liver lesion (DLL) at baseline and 2 months after chemotherapy. RECIST1·1 evaluation was performed at 6 months. A radiomic signature (Survival PrEdiction in patients treated by FOLFIRI and bevacizumab for mCRC using contrast-enhanced CT TextuRe Analysis (SPECTRA) Score) combining the significant predictive features was built using multivariable Cox analysis in 120 patients, then locked, and validated in 110 patients. Overall survival (OS) was estimated with the Kaplan-Meier method and compared between groups with the logrank test. An external validation was performed in another cohort of 40 patients from the PRODIGE 20 Trial. Results: In the training cohort, the significant predictive features for OS were: decrease in sum of the target liver lesions (STL), (adjusted hasard-ratio(aHR)=13·7, p=1·93×10 –7 ), decrease in kurtosis (ssf=4) (aHR=1·08, p=0·001) and high baseline density of DLL, (aHR=0·98, p<0·001). Patients with a SPECTRA Score >0·02 had a lower OS in the training cohort (p<0·0001), in the validation cohort (p<0·0008) and in the external validation cohort (p=0·0027). SPECTRA Score at 2 months had the same prognostic value as RECIST at 6 months, while non-response according to RECIST1·1 at 2 months was not associated with a lower OS in the validation cohort (p=0·238). Morphological response was not associated with OS (p=0·41). Conclusion: A radiomic signature (combining decrease in STL, density and computed texture analysis of the DLL) at baseline and 2-month CT was able to predict OS, and identify good responders better than RECIST1.1 criteria in patients with mCRC treated by FOLFIRI and bevacizumab as a first-line treatment. This tool should now be validated by further prospective studies. Trial registration: Clinicaltrial.gov identifier of the PRODIGE 9 study: NCT00952029 . Clinicaltrial.gov identifier of the PRODIGE 20 study: NCT01900717 .